Scarica l'app Stockscreener
128.20
0.11%
-0.14
Dopo l'orario di chiusura:
128.20
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BPMC Giù?
Forum
Previsione
Precedente Chiudi:
$128.34
Aprire:
$128.35
Volume 24 ore:
2.30M
Relative Volume:
0.90
Capitalizzazione di mercato:
$8.26B
Reddito:
$434.41M
Utile/perdita netta:
$-128.05M
Rapporto P/E:
-60.76
EPS:
-2.11
Flusso di cassa netto:
$-250.52M
1 W Prestazione:
-0.04%
1M Prestazione:
+0.32%
6M Prestazione:
+47.02%
1 anno Prestazione:
+16.17%
Intervallo 1D:
$128.20
$128.45
Intervallo di 1 settimana:
$128.06
$128.52
Portata 52W:
$73.04
$128.52
Blueprint Medicines Corp Stock (BPMC) Company Profile
Nome
Blueprint Medicines Corp
Settore
Industria
Telefono
617-374-7580
Indirizzo
45 SIDNEY STREET, CAMBRIDGE, MA
Confronta BPMC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BPMC
Blueprint Medicines Corp
|
128.20 | 8.26B | 434.41M | -128.05M | -250.52M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-03-20 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-03-18 | Iniziato | Wolfe Research | Outperform |
| 2025-03-17 | Iniziato | Jefferies | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-11-14 | Iniziato | JP Morgan | Overweight |
| 2024-10-24 | Iniziato | UBS | Neutral |
| 2024-05-14 | Iniziato | Stephens | Overweight |
| 2024-05-06 | Aggiornamento | Leerink Partners | Underperform → Market Perform |
| 2023-10-27 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-08-21 | Reiterato | Needham | Buy |
| 2023-07-31 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-06-05 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2023-01-03 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-11-02 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-09-14 | Iniziato | Berenberg | Buy |
| 2022-07-08 | Iniziato | Oppenheimer | Outperform |
| 2022-06-27 | Iniziato | Wells Fargo | Underweight |
| 2022-06-10 | Downgrade | Citigroup | Neutral → Sell |
| 2022-06-01 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-03-01 | Iniziato | Citigroup | Neutral |
| 2022-02-17 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-01-25 | Aggiornamento | Stifel | Hold → Buy |
| 2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-09-30 | Ripresa | Stifel | Hold |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-31 | Iniziato | Credit Suisse | Neutral |
| 2020-12-03 | Iniziato | Stifel | Hold |
| 2020-11-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-02 | Downgrade | Jefferies | Buy → Hold |
| 2020-10-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-15 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-05 | Iniziato | Barclays | Equal Weight |
| 2020-03-17 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-11-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-10-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-10-03 | Iniziato | H.C. Wainwright | Buy |
| 2019-09-12 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-08-29 | Iniziato | Piper Jaffray | Neutral |
| 2019-08-15 | Ripresa | Raymond James | Mkt Perform |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2019-05-23 | Ripresa | Goldman | Buy |
| 2019-04-03 | Iniziato | Morgan Stanley | Overweight |
| 2018-09-25 | Iniziato | Leerink Partners | Outperform |
| 2017-12-11 | Reiterato | Goldman | Buy |
Mostra tutto
Blueprint Medicines Corp Borsa (BPMC) Ultime notizie
Blueprint Medicines (BPMC) Downgraded by Wells Fargo Amid Acquis - GuruFocus
BPMC: Wells Fargo Downgrades Blueprint Medicines, Lowers Price Target | BPMC Stock News - GuruFocus
Sanofi, Blueprint Medicines filed HSR June 9 - MLex
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, SVT, SSBK on Behalf of Shareholders - GlobeNewswire Inc.
Blueprint Medicines’ SWOT analysis: stock poised for growth amid Sanofi acquisition - Investing.com
Blueprint Medicines (BPMC) Showcases Groundbreaking Data on Syst - GuruFocus
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses - PR Newswire
Blueprint Medicines Stock Experiences Wild Intraday Swing, Closes Flat Amid Strong Momentum - Daily Chhattisgarh News
Blueprint Medicines stock hits all-time high of $128.3 By Investing.com - Investing.com Canada
Blueprint Medicines stock hits all-time high of $128.3 - Investing.com
Sanofi to Buy Immunology Biotech Blueprint for $9.1 Billion - MSN
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta - Benzinga
Blueprint Medicines (BPMC): Morgan Stanley Raises Price Target | BPMC Stock News - GuruFocus
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal - TradingView
Citigroup Upgrades Blueprint Medicines (BIT:1BPMC) - Nasdaq
Sanofi to acquire Blueprint Medicines for about $9.1B - Drug Store News
Blueprint Medicines (BPMC) Target Price Raised by UBS Analyst | - GuruFocus
Blueprint Medicines (BPMC) Target Price Raised by UBS Analyst | BPMC Stock News - GuruFocus
Blueprint Medicines (BPMC) Sees Price Target Increase Amid Acquisition News | BPMC Stock News - GuruFocus
Sanofi to buy Blueprint Medicines for $9.1B - MSN
Blueprint Medicines (BPMC) Target Price Increased Following Acqu - GuruFocus
Blueprint Medicines (BPMC) Target Price Increased Following Acquisition News | BPMC Stock News - GuruFocus
Stephens & Co. Downgrades Blueprint Medicines (BPMC) to Equal Weight, Cuts PT - Insider Monkey
Citizens JMP Downgrades Blueprint Medicines (BPMC) to Market Perform - Insider Monkey
Sanofi to Buy Blueprint for $9.1 Billion Equity Value - MSN
Nasdaq Today Blueprint Medicines Reclassified Kalkine - Kalkine Media
BPMC Stock Upgraded: Citigroup Raises Price Target Significantly - GuruFocus
BPMC Stock Upgraded: Citigroup Raises Price Target Significantly | BPMC Stock News - GuruFocus
Citi upgrades Blueprint Medicines stock rating after Sanofi acquisition - Investing.com
Blueprint Medicines (BPMC) Sees Upgrade and Acquisition by Sanof - GuruFocus
Blueprint Medicines Stock Surges as Sanofi Announces $9.5 Billion Acquisition - MSN
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines CorporationBPMC - Business Wire
Blueprint Medicines Corporation (BPMC) Downgraded at TD Cowen - Insider Monkey
Wolfe Research Lowered Blueprint Medicines Corporation (BPMC) from Outperform to Peer Perform - Insider Monkey
Blueprint Medicines (BPMC) Downgraded Following Acquisition News - GuruFocus
Blueprint Medicines (BPMC) Downgraded Following Acquisition News | BPMC Stock News - GuruFocus
Blueprint Medicines downgraded to Neutral from Buy at Guggenheim - TipRanks
Guggenheim Downgrades Blueprint Medicines to Neutral From Buy, Price Target is $132 - marketscreener.com
Sanofi to acquire Blueprint for up to $9.5B - Pharma Voice
Blueprint Medicines (BPMC) Downgraded by JMP Securities | BPMC S - GuruFocus
Blueprint Medicines (BPMC) Downgraded by JMP Securities | BPMC Stock News - GuruFocus
Blueprint Medicines (BPMC) Receives Downgrade from Stephens & Co - GuruFocus
Blueprint Medicines (BPMC) Receives Downgrade from Wolfe Research | BPMC Stock News - GuruFocus
Wolfe Downgrades Blueprint Medicines to Peer Perform From Outperform - marketscreener.com
Blueprint Medicines (BPMC) Downgraded Following Acquisition Deal - GuruFocus
Stephens Downgrades Blueprint Medicines to Equalweight From Overweight, Adjusts PT to $135 From $150 - marketscreener.com
JPMorgan Downgrades Blueprint Medicines to Neutral From Overweight, Adjusts PT to $129 From $130 - marketscreener.com
Sanofi to acquire US biotech firm Blueprint for up to $9.5bn - World Pharmaceutical Frontiers
Blueprint Medicines (BPMC) Downgraded Amid Sanofi Acquisition Pr - GuruFocus
Blueprint Medicines (BPMC) Downgraded Amid Sanofi Acquisition Proposal | BPMC Stock News - GuruFocus
Citizens JMP downgrades Blueprint Medicines stock on Sanofi acquisition - Investing.com
Blueprint Medicines Corp Azioni (BPMC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Blueprint Medicines Corp Azioni (BPMC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Albers Jeffrey W. | Director |
May 27 '25 |
Option Exercise |
36.05 |
5,000 |
180,250 |
151,630 |
| Albers Jeffrey W. | Director |
May 27 '25 |
Sale |
101.14 |
5,000 |
505,692 |
146,630 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):